A hypothesis‐generating exploratory analysis of samples from patients with HER2‐low breast cancer treated with Trastuzumab‐Deruxtecan in the J101 trial provided evidence to support the notion that the dynamic range and precise quantification offered by QCS may allow for additional tailoring of the treatment in patients with HER2‐low breast cancer [5]. Here, ERBB2 is linked to breast carcinoma.